home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

A Sweet Route To Treating Alzheimer's Disease?

  July, 10 2008 8:19
your information resource in human molecular genetics

Scientists have identified an enzyme inhibitor in the brain that reduces the phosphorylation of a key protein known to be associated with Alzheimer's disease. The research, published online in Nature Chemical Biology, could lead to a new strategy for developing therapeutic treatments for patients with Alzheimer's disease.

Hyperphosphorylated tau proteins tend to collect into clusters called neurofibrillary tangles. The presence of these tangles in the brain is a major hallmark of Alzheimer's disease and associated neurodegenerative diseases called 'tauopathies'. Scientists think that tau phosphorylation may have a reciprocal relationship with tau O-GlcNAcylation, or addition of a particular type of sugar molecule to tau. This means that increasing the levels of the sugar O-GlcNAc should decrease tau phosphorylation.

One way to increase tau O-GlcNAc levels is to inhibit the enzyme that removes the sugar from tau. The O-GlcNAcase inhibitors created so far are unstable within the body, difficult to synthesize or unable to enter the brain from the bloodstream. David Vocadlo and colleagues have created an inhibitor that overcomes these problems and shown that it elevates O-GlcNAc and lowers tau phosphorylation within the body.

With this inhibitor it will now be possible to investigate O-GlcNAcase as a target for treating Alzheimer's disease and also to explore the role of O-GlcNAc in the brain.

Author contact:

David J. Vocadlo (Simon Fraser University, Burnaby, BC, Canada)
Email: dvocadlo@sfu.ca

Abstract available online.

(C) Nature Chemical Biology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.